For cardiac muscle (but also to a lower extent for skeletal muscle, see later), a very well-studied inhibitor of myosin motors is the MyoKardia’s mavacamten, currently an FDA-approved treatment, commercialized under the name of camzyosTM, that targets the source of symptomatic obstructive Hypertrophic CardioMyopathy (HCM). The gene discussed is MYH14; the disease is hypertrophic cardiomyopathy.